English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Determining treatment response for patients with hidradenitis suppurativa ( HS ) can be challenging due to limitations of current disease activity evaluations.    Objective  Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (Hi SCR ) and its utility as an outcome measure.    Methods  Patients with baseline total abscess and inflammatory nodule count ( AN  count) of at least three and draining fistula count of 20 or fewer comprised the  post hoc  subpopulation analysed. Hi SCR  (at least a 50% reduction in total  AN  count, with no increase in abscess count, and no increase in draining fistula count relative to baseline) and  HS ‐ PGA  Response [Hidradenitis Suppurativa‐Physician's Global Assessment score of clear, minimal, or mild, with at least a 2‐grade improvement from baseline] were used to evaluate patient response after adalimumab treatment weekly, every other week, or placebo (1 : 1 : 1).    Results  The subpopulation included 132 (85.7%) patients; 70.5% women and 73.5% white. At week 16, Hi SCR  was achieved by 54.5% receiving weekly adalimumab, 33.3% every other week, and 25.6% placebo and  HS ‐ PGA  Response was achieved by 20.5% receiving weekly adalimumab, 6.7% every other week and 2.3% placebo.    Conclusion  Hi SCR  was more responsive to change than  HS ‐ PGA  Response in this subpopulation.

journal of the european academy of dermatology and venereology

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study